The impact of the COVID-19 pandemic on renal cancer care
ConclusionsThe COVID-19 pandemic resulted in fewer RCC diagnoses, especially T1a/T1b tumors. Treatment-related changes appeared to be limited, temporarily and in accordance with the adapted guidelines. The diagnostic delay could lead to more advanced RCCs in later years but there are no indications for this yet. (Source: World Journal of Urology)
Source: World Journal of Urology - April 13, 2024 Category: Urology & Nephrology Source Type: research
PSAT1 enhances the efficacy of the prognosis estimation nomogram model in stage-based clear cell renal cell carcinoma
Clear cell renal cell carcinoma (ccRCC) is associated with a high prevalence of cancer-related deaths. The survival rates of patients are significantly lower in late-stage ccRCC than in early-stage ccRCC, due ... (Source: BMC Cancer)
Source: BMC Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Jun Wang, Xiaoming He, Yuanyuan Mi, Yong Q. Chen, Jie Li and Rong Wang Tags: Research Source Type: research
Pioglitazone ameliorates ischemia/reperfusion-induced acute kidney injury via oxidative stress attenuation and NLRP3 inflammasome
AbstractAcute kidney injury (AKI) induced by renal ischemia/reperfusion injury (IRI) is a severe clinical condition. ROS accumulation, antioxidant pathways deficiency, and inflammation are involved in IRI. Pioglitazone (Pio) exerts anti-inflammatory and antioxidant effects. The aim of this study was to explore the protective effects of pioglitazone against IRI-induced AKI. Pathogen-free Sprague –Dawley (SD) rats were arbitrarily divided into four groups: Sham operation group Control (CON) group, CON + Pio group, I/R + Saline group, and I/R + Pio group. In addition, HK-2 cells were subjected to hypoxia and reo...
Source: Human Cell - April 12, 2024 Category: Cytology Source Type: research
Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma
ConclusionsPBRM1 and RAD51 dual-loss ccRCC indicates superior responses to immunotherapy. Dual-loss ccRCC harbors an immune-desert microenvironment but enriched with M1 macrophages. Dual-loss ccRCC is susceptible to defective homologous recombination but possesses high chromosomal stability. (Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - April 12, 2024 Category: Cancer & Oncology Source Type: research
Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
Expert Rev Anticancer Ther. 2024 Apr 10. doi: 10.1080/14737140.2024.2341734. Online ahead of print.ABSTRACTINTRODUCTION: Immunotherapy represents a significant and essential component of renal carcinoma therapy, but the selection of an optimal regimen for an individual patient remains unclear. Despite significant improvements in therapeutic options for RCC, predictive biomarkers for immunotherapeutic agents remain elusive. Neopterin is a biomarker of cell-mediated immune response, with concentrations increased in different disorders, including cancer. High neopterin levels herald, in general, a poor prognosis.AREAS COVERED...
Source: Expert Review of Anticancer Therapy - April 10, 2024 Category: Cancer & Oncology Authors: Hana Studentova Katerina Hola Bohuslav Melichar Martina Spisarova Source Type: research
Pro-cancer role of CD276 as a novel biomarker for clear cell renal cell carcinoma
CONCLUSION: CD276 expression was significantly increased in ccRCC tissues and cells and positively correlated with patient prognosis. CD276 is a potential prognostic biomarker of ccRCC. Overall, this study provides a potential therapeutic strategy for ccRCC.PMID:38600002 | DOI:10.1016/j.urolonc.2024.03.018 (Source: Cancer Control)
Source: Cancer Control - April 10, 2024 Category: Cancer & Oncology Authors: Zhi-Yu Zhang Jian-Hao Xu Jiang-Lei Zhang Yu-Xin Lin Jun Ou-Yang Source Type: research
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival
CONCLUSIONS: Our findings illustrate that G47Δ-mIL2 is efficacious, stimulates antitumor immunity against orthotopic GBM, and may also target GSC. OHSV expressing IL-2 may represent an agent that merits further exploration in patients with GBM.PMID:38599661 | DOI:10.1136/jitc-2024-008880 (Source: Herpes)
Source: Herpes - April 10, 2024 Category: Infectious Diseases Authors: Praveen K Bommareddy Hiroaki Wakimoto Robert L Martuza Howard L Kaufman Samuel D Rabkin Dipongkor Saha Source Type: research
Pro-cancer role of CD276 as a novel biomarker for clear cell renal cell carcinoma
CONCLUSION: CD276 expression was significantly increased in ccRCC tissues and cells and positively correlated with patient prognosis. CD276 is a potential prognostic biomarker of ccRCC. Overall, this study provides a potential therapeutic strategy for ccRCC.PMID:38600002 | DOI:10.1016/j.urolonc.2024.03.018 (Source: Urologic Oncology)
Source: Urologic Oncology - April 10, 2024 Category: Urology & Nephrology Authors: Zhi-Yu Zhang Jian-Hao Xu Jiang-Lei Zhang Yu-Xin Lin Jun Ou-Yang Source Type: research
Choroidal metastases from primary renal cell carcinoma
J Fr Ophtalmol. 2024 Apr 9:104179. doi: 10.1016/j.jfo.2024.104179. Online ahead of print.NO ABSTRACTPMID:38599890 | DOI:10.1016/j.jfo.2024.104179 (Source: Journal Francais d Ophtalmologie)
Source: Journal Francais d Ophtalmologie - April 10, 2024 Category: Opthalmology Authors: T Boutaj S Tachfouti L Sbai Y Laarif H El Ghazi A Chefchaouni H Lazaar R Benkirane S Moutamani R El Hachimi S Benchekroun Belabbes A Amazouzi O Cherkaoui Source Type: research
Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
Expert Rev Anticancer Ther. 2024 Apr 10. doi: 10.1080/14737140.2024.2341734. Online ahead of print.ABSTRACTINTRODUCTION: Immunotherapy represents a significant and essential component of renal carcinoma therapy, but the selection of an optimal regimen for an individual patient remains unclear. Despite significant improvements in therapeutic options for RCC, predictive biomarkers for immunotherapeutic agents remain elusive. Neopterin is a biomarker of cell-mediated immune response, with concentrations increased in different disorders, including cancer. High neopterin levels herald, in general, a poor prognosis.AREAS COVERED...
Source: Expert Review of Anticancer Therapy - April 10, 2024 Category: Cancer & Oncology Authors: Hana Studentova Katerina Hola Bohuslav Melichar Martina Spisarova Source Type: research
Machine learning-based integration develops a stress response stated T cell (Tstr)-related score for predicting outcomes in clear cell renal cell carcinoma
CONCLUSIONS: This study provides a Tstr cell-related score for predicting outcomes and PD-1 blockade therapy response in ccRCC. Tstr cells may exert their pro-tumoral role in ccRCC, acting against mast cells, in the acute inflammatory tumor microenvironment. TNFSF13B could serve as a key biomarker related to TCs.PMID:38599101 | DOI:10.1016/j.intimp.2024.112017 (Source: International Immunopharmacology)
Source: International Immunopharmacology - April 10, 2024 Category: Allergy & Immunology Authors: Shuai Yang Zhaodong Han Zeheng Tan Zhenjie Wu Jianheng Ye Shanghua Cai Yuanfa Feng Huichan He Biyan Wen Xuejin Zhu Yongkang Ye Huiting Huang Sheng Wang Weide Zhong Yulin Deng Source Type: research
Pro-cancer role of CD276 as a novel biomarker for clear cell renal cell carcinoma
CONCLUSION: CD276 expression was significantly increased in ccRCC tissues and cells and positively correlated with patient prognosis. CD276 is a potential prognostic biomarker of ccRCC. Overall, this study provides a potential therapeutic strategy for ccRCC.PMID:38600002 | DOI:10.1016/j.urolonc.2024.03.018 (Source: Urologic Oncology)
Source: Urologic Oncology - April 10, 2024 Category: Urology & Nephrology Authors: Zhi-Yu Zhang Jian-Hao Xu Jiang-Lei Zhang Yu-Xin Lin Jun Ou-Yang Source Type: research
Choroidal metastases from primary renal cell carcinoma
J Fr Ophtalmol. 2024 Apr 9:104179. doi: 10.1016/j.jfo.2024.104179. Online ahead of print.NO ABSTRACTPMID:38599890 | DOI:10.1016/j.jfo.2024.104179 (Source: Journal Francais d Ophtalmologie)
Source: Journal Francais d Ophtalmologie - April 10, 2024 Category: Opthalmology Authors: T Boutaj S Tachfouti L Sbai Y Laarif H El Ghazi A Chefchaouni H Lazaar R Benkirane S Moutamani R El Hachimi S Benchekroun Belabbes A Amazouzi O Cherkaoui Source Type: research
Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
Expert Rev Anticancer Ther. 2024 Apr 10. doi: 10.1080/14737140.2024.2341734. Online ahead of print.ABSTRACTINTRODUCTION: Immunotherapy represents a significant and essential component of renal carcinoma therapy, but the selection of an optimal regimen for an individual patient remains unclear. Despite significant improvements in therapeutic options for RCC, predictive biomarkers for immunotherapeutic agents remain elusive. Neopterin is a biomarker of cell-mediated immune response, with concentrations increased in different disorders, including cancer. High neopterin levels herald, in general, a poor prognosis.AREAS COVERED...
Source: Expert Review of Anticancer Therapy - April 10, 2024 Category: Cancer & Oncology Authors: Hana Studentova Katerina Hola Bohuslav Melichar Martina Spisarova Source Type: research
Pro-cancer role of CD276 as a novel biomarker for clear cell renal cell carcinoma
CONCLUSION: CD276 expression was significantly increased in ccRCC tissues and cells and positively correlated with patient prognosis. CD276 is a potential prognostic biomarker of ccRCC. Overall, this study provides a potential therapeutic strategy for ccRCC.PMID:38600002 | DOI:10.1016/j.urolonc.2024.03.018 (Source: Urologic Oncology)
Source: Urologic Oncology - April 10, 2024 Category: Urology & Nephrology Authors: Zhi-Yu Zhang Jian-Hao Xu Jiang-Lei Zhang Yu-Xin Lin Jun Ou-Yang Source Type: research
